On This Page

Filter

These are the filters currently being used to limit the search results. Click on the
icon to remove the filter.

date

2014-10-23

uin

211732

Sort by

This list shows the properties that you can sort by. Click on to sort in ascending order and to sort in descending order. The properties that you're currently sorting by are
shown at the top of the list. Click on to remove a sort and or to reverse the current sort order. Click on the icon to remove all the sorting. Note that sorting can significantly slow down the
loading of the page.

View

Choose what information you want to view about each item. There are some pre-defined
views, but starred properties are always present no matter what the view. You can
star properties by clicking on the icon. The currently starred icons have a icon; clicking on it will unstar the property.

<p>The following table shows estimated expenditure on research on asthma, motor neurone
disease (MND) and osteoporosis by the Medical Research Council, other Research Councils
and Innovate UK, and by the National Institute for Health (NIHR) through its research
programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p>
</p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td
colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del
class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del
class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del
class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del
class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del
class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del
class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del
class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del
class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del
class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del
class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td
colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td
colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p>
</p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution
and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p>
</p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the
figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these
diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating
to development of new drugs for asthma, MND and osteroporosis occurs primarily through
NIHR research infrastructure including the CRN and cannot be disaggregated from total
expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the
development of new drugs for asthma, MND or osteoporosis is not available.</p><p>
</p>